European regulators have refused to back GlaxoSmithKline’s daily triple therapy Trelegy Ellipta for asthma, denying a label extension because there was no evidence to show a reduction of flare-ups.

Now, it has decided to publish a special report on two of GSK's COPD therapies – Breo Ellipta (fluticasone furoate and vilanterol) and Trelegy Ellipta (fluticasone furoate, umeclidinium ...

Amanda Southcombe, GSK NZ General Manager, says funding for Trelegy Ellipta was recently announced, a single inhaler triple-therapy to treat the disease, which will see around 15,000 Kiwis ...

Amanda Southcombe, GSK NZ General Manager, says funding for Trelegy Ellipta was recently announced, a single inhaler triple-therapy to treat the disease, which will see around 15,000 Kiwis suffering ...

Amanda Southcombe, GSK NZ general manager, says funding for Trelegy Ellipta was recently announced, a single inhaler triple-therapy to treat the disease, which will see around 15,000 Kiwis ...

This upside was driven by solid sales growth of the asthma inhaler Trelegy Ellipta across all regions, reflecting patient demand. The adverse impact of removing the Average Manufacturer Price (AMP ...

We need better utilisation of funding, more clinicians, and greater access to diagnostics,” he said. Amanda Southcombe, General Manager of GSK NZ, said recent funding for Trelegy Ellipta, a ...